AQST
Aquestive Therapeutics, Inc.Company Information
- Company Name
- Aquestive Therapeutics, Inc.
- CIK
- CIK0001398733
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- AQST: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- AQST
SEC filing data through
Insider Sentiment
- Last purchase
- —
- Last sale
- 2026-06-23
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 730,717
Institutional Sentiment
- As of
- 2026-03-31
- Institutional shares owned
- 64,843,906
- Shares outstanding
- 122,609,995
- Ownership
- 52.89%
Earnings Market Reaction
- Filing date
- 2026-08-11
- Price on filing date
- —
- 1-month reaction
- 21.09%
- 3-month reaction
- Pending
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 98 | 111 | 121 | 129 | 61 | 69 | 72 | 78 | 90 | 95 | 24 | 25 | ||||||
| Receivables Net Current | 9 | 7 | 18 | - | - | - | 7 | - | - | - | 8 | - | ||||||
| Inventory Net | 7 | 8 | 6 | 8 | 8 | 7 | 6 | 7 | 7 | 8 | 7 | 7 | ||||||
| Prepaid Expense And Other Assets Current | 3 | 5 | 4 | 3 | 1 | 3 | 3 | 2 | 1 | 2 | 2 | 2 | ||||||
| Assets Current | 118 | 130 | 149 | 152 | 82 | 89 | 88 | 97 | 104 | 113 | 41 | 42 | ||||||
| Property Plant And Equipment Net | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 5 | ||||||
| Operating Lease Right Of Use Asset | 8 | 4 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 6 | 6 | ||||||
| Finite Lived Intangible Assets Net | - | - | 0 | - | - | 0 | 0 | 0 | 0 | 1 | 1 | 1 | ||||||
| Other Assets Noncurrent | 2 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 5 | 5 | 5 | ||||||
| Assets | 132 | 141 | 160 | 164 | 94 | 102 | 101 | 110 | 118 | 130 | 57 | 59 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 9 | 12 | 30 | 11 | 12 | 12 | 10 | 8 | 6 | 11 | 9 | 10 | ||||||
| Accrued Liabilities Current | 5 | 3 | 5 | 5 | 5 | 3 | 6 | 5 | 6 | 5 | 6 | 5 | ||||||
| Operating Lease Liability Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | ||||||
| Contract With Customer Liability Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 3 | ||||||
| Lines Of Credit Current | - | - | 10 | - | - | - | 0 | - | - | - | 0 | - | ||||||
| Loans Payable Current | - | 14 | - | 6 | 3 | 0 | - | 0 | 0 | 0 | - | 5 | ||||||
| Debt Current | 0 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Liabilities Current | 16 | 32 | 48 | 26 | 23 | 18 | 19 | 15 | 14 | 18 | 18 | 24 | ||||||
| Long Term Loans Payable | - | - | - | - | - | - | - | - | - | - | - | 35 | ||||||
| Unsecured Long Term Debt | - | - | - | - | - | - | - | 19 | 17 | 16 | - | - | ||||||
| Long Term Debt And Capital Lease Obligations | 51 | 25 | 28 | - | - | - | 33 | - | - | - | 28 | - | ||||||
| Operating Lease Liability Noncurrent | 8 | 4 | 4 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 6 | ||||||
| Contract With Customer Liability Noncurrent | 19 | 19 | 19 | 20 | 20 | 20 | 20 | 20 | 22 | 32 | 32 | 33 | ||||||
| Other Liabilities Noncurrent | 6 | 6 | 7 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||
| Liabilities | 189 | 175 | 194 | 168 | 166 | 163 | 162 | 155 | 153 | 166 | 164 | 162 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 421 | 421 | 413 | 411 | 327 | 325 | 303 | 301 | 299 | 296 | 213 | 208 | ||||||
| Retained Earnings Accumulated Deficit | -478 | -455 | -447 | -415 | -400 | -386 | -363 | -346 | -335 | -332 | -319 | -311 | ||||||
| Stockholders Equity | -57 | -34 | -34 | -4 | -73 | -61 | -60 | -45 | -35 | -36 | -106 | -103 | ||||||
| Liabilities And Stockholders Equity | 132 | 141 | 160 | 164 | 94 | 102 | 101 | 110 | 118 | 130 | 57 | 59 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | ||||||
| Common Stock Shares Issued | 126 | 124 | 122 | 122 | 99 | 99 | 91 | 91 | 91 | 90 | 69 | 67 | ||||||
| Shares Outstanding | 126 | 124 | 122 | 122 | 99 | 99 | 91 | 91 | 91 | 90 | 69 | 67 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialAquestive Therapeutics, Inc. (AQST) — SEC Financial Statements & Analysis
Aquestive Therapeutics, Inc. (AQST) is a pharmaceutical preparations company, incorporated in DE. Aquestive Therapeutics, Inc. trades on Nasdaq as: AQST. Aquestive Therapeutics, Inc. (AQST)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-11. Based on that filing, Aquestive Therapeutics, Inc. carries a market cap of $519.98M, a P/E ratio of -6.65x, a P/B ratio of -9.19x, a P/S ratio of 9.61x, an enterprise value of $472.17M, and an EV/EBITDA multiple of -9.04x. On profitability, it posts a gross margin of 67.04%, an operating margin of -97.52%, a net margin of -144.63%, a Return on Equity (ROE) of 121.12%, and a Return on Assets (ROA) of -69.29%. Per share, it reports EPS of $-0.63, diluted EPS of $-0.63, free cash flow per share of $-0.37, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 22.56% year-over-year, net income growth of 20.27% year-over-year, and EPS growth of -4.43% year-over-year. On the balance sheet, it maintains a current ratio of 7.19x, a quick ratio of 6.54x, working capital of $102.02M, a debt-to-equity ratio of -3.33x, a debt ratio of 1.43, an interest coverage ratio of -4.68x, free cash flow of $-45.95M (TTM), and net debt of $-47.80M. Figures sourced from SEC EDGAR.
- Market Cap
- $519.98M
- P/E TTM
- -6.65x
- EPS TTM
- $-0.63
- P/B TTM
- -9.19x
- ROE TTM
- 121.12%
- ROA TTM
- -69.29%
- Debt To Equity
- -3.33x
- Free Cash Flow TTM
- $-45.95M
- Net Revenue TTM Growth 1Y
- 22.56%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Aquestive Therapeutics, Inc. in?
Aquestive Therapeutics, Inc. (AQST) operates in the Pharmaceutical Preparations industry.
What exchange does AQST trade on?
Aquestive Therapeutics, Inc. (AQST) trades on the Nasdaq.
Where is Aquestive Therapeutics, Inc. incorporated?
Aquestive Therapeutics, Inc. is incorporated in DE.
When was Aquestive Therapeutics, Inc. (AQST)'s most recent SEC filing?
Aquestive Therapeutics, Inc. (AQST)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-11.
What is AQST's market cap?
Aquestive Therapeutics, Inc. (AQST) has a market capitalization of $519.98M as of 2026-06-30.
What is AQST's EPS (earnings per share)?
Aquestive Therapeutics, Inc. (AQST)'s trailing twelve month EPS is $-0.63 as of 2026-06-30.
What is AQST's ROE (return on equity)?
Aquestive Therapeutics, Inc. (AQST)'s trailing twelve month Return on Equity (ROE) is 121.12% as of 2026-06-30.
What is AQST's ROA (return on assets)?
Aquestive Therapeutics, Inc. (AQST)'s trailing twelve month Return on Assets (ROA) is -69.29% as of 2026-06-30.
What is AQST's EV/EBITDA?
Aquestive Therapeutics, Inc. (AQST)'s trailing twelve month EV/EBITDA is -9.04x as of 2026-06-30.